Synsam AB (SYNSAM) Fair Value & Analysis
Healthcare · SE · Market cap 7.9B SEK
Fair value as of: Jul 16, 2026
From 24 valuation models · updated 25 days ago
Fair value updated Jul 16, 2026, revised from kr 70.36 to kr 63.38 (−9.9%) since Jun 24, 2026.
A solid business, screening 14% undervalued on our models.
What matters now
- A fairly wide model range (kr 41.61 to kr 85.15) leaves room in how you read the outcome.
- Our model range runs from kr 41.61 (bear) to kr 85.15 (bull), base kr 63.38. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 66/100 (solid quality) with high evidence: the data supports the verdict.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 16, 2026.
How to read this chart
57‑month range kr 30.11 – kr 67.96 · fair‑value band kr 41.61 – kr 85.15 · the kr 55.70 price screens below the kr 63.38 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 16, 2026.
Analysis
Synsam AB (SYNSAM) currently trades at kr 55.70, while our model-based Fair Value estimate is kr 63.38, implying the stock looks roughly 13.8% undervalued today. The Quality Score stands at 66/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, Synsam AB generated revenue of 7.1B SEK at a net margin of 7.0%. Revenue grew 3.8% year over year. It earns a return on equity of 19.6%. Net debt stands at 3.4B SEK. Fundamentals as of Jul 16, 2026
Our scenario range runs from kr 41.61 (bear case) to kr 85.15 (bull case); at kr 55.70, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 20% below its 52-week high and 19% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at 14%, SYNSAM screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: DCF Models (kr 87.42) versus Asset-Based (kr 11.50). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 16, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 62 · Market factors (momentum, volatility) 52
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Synsam AB (publ), together with its subsidiaries, operates in the optical retail and eye health sector in the Nordic Region. The company offers lenses, frames, sunglasses, sports spectacles, contact lenses, eye care accessories, and hearing aids.
Full company description
Synsam AB (publ), together with its subsidiaries, operates in the optical retail and eye health sector in the Nordic Region. The company offers lenses, frames, sunglasses, sports spectacles, contact lenses, eye care accessories, and hearing aids. It also provides eye health services, hearing tests, lifestyle subscriptions, contact lens subscriptions, personal style advice services, and eye examination services, including physical and online examination services. The company offers its products and services through directly owned and franchised stores, as well as through e-commerce warehouses in Sweden, Denmark, Norway, Iceland, Faroe Islands, and Finland under the Synsam, Profil Optik, Fellepini, Oscar Eide, EyeQ , Jämtö, and Index brands. Synsam AB (publ) was founded in 1968 and is headquartered in Stockholm, Sweden.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Synsam AB reported revenue of kr 7.1B in FY2025 versus kr 4.7B in FY2021, a compound +10.6%/yr. Reported net income was kr 454M in FY2025, compounding +72.7%/yr from FY2021.
Watch SYNSAM: get an alert when its fair value changes →
Peer Group
Medical Instruments & Supplies · 203 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Instruments & Supplies median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 16, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $402.33 | $150.04 | -63% |
| EssilorLuxottica Société anonyme 1EL | €172.45 | €68.55 | -60% |
| Medline Inc MDLN | $41.11 | $30.15 | -27% |
| Becton, Dickinson and Company BDX | $150.65 | $103.53 | -31% |
| Alcon Inc ALC | $70.26 | $39.78 | -43% |
| ResMed Inc RMD | $203.87 | $187.89 | -8% |
| West Pharmaceutical Services, Inc WST | $353.71 | $143.97 | -59% |
| Straumann Holding STMN | CHF 106.00 | CHF 47.31 | -55% |
| Sartorius Stedim Biotech S.A DIM | €188.50 | €51.16 | -73% |
| Coloplast A/S COLOB | kr 414.00 | kr 382.22 | -8% |
Compare Synsam AB with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Synsam AB (SYNSAM) overvalued or undervalued?
What is the fair value of SYNSAM?
What is the quality score of SYNSAM?
What is the revenue of Synsam AB (SYNSAM)?
What is the net profit margin of SYNSAM?
Does Synsam AB pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Synsam AB and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.